Diabetes and obesity drugs fuel Eli Lilly profit in the final quarter of 2024
Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker debuted a mostly better-than-expected 2025 forecast
![Diabetes and obesity drugs fuel Eli Lilly profit in the final quarter of 2024](https://static.independent.co.uk/2025/02/06/14/Earns_Eli_Lilly_46583.jpg?width=1200&auto=webp#)